On October 30, 2017 Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, reported that on November 7, 2017, the Company will release its financial results for the quarter ended September 30, 2017 (Press release, Affimed, OCT 30, 2017, View Source [SID1234521338]). The Company’s management team will host a conference call to discuss the Company’s financial results and recent corporate developments on Tuesday, November 7, 2017 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3213767.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Local – Amsterdam, the Netherlands: +31 (0)20 716 8295

Local – Copenhagen, Denmark: +45 32 71 16 60

Local – Frankfurt, Germany: +49 (0)69 2222 10625

Local – Zurich, Switzerland: +41 (0)44 580 7214

Local – London, U.K.: +44 (0)20 3427 1907

Local – New York City, U.S.A.: +1 646 254 3366

Local – Paris, France: +33 (0)1 76 77 22 23

An audio webcast of the conference call can be accessed in the “Events” section on the “Investors & Media” page of the Affimed website at View Source A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.